Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALMS NASDAQ:BEAM NASDAQ:DRUG NASDAQ:MOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALMSAlumis$22.02$23.84$2.76▼$30.60$2.81B-0.31938,215 shs567,254 shsBEAMBeam Therapeutics$28.64$27.66$15.35▼$36.44$2.95B2.262.24 million shs1.33 million shsDRUGBright Minds Biosciences$83.50$80.83$23.17▼$123.75$812.64M-5.35226,720 shs281,059 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALMSAlumis0.00%-3.72%-11.67%-20.36%+351.23%BEAMBeam Therapeutics0.00%+2.54%+5.64%+1.09%+70.17%DRUGBright Minds Biosciences0.00%+7.78%-6.35%-3.47%+187.83%MORMorphoSys0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALMSAlumis$22.02$23.84$2.76▼$30.60$2.81B-0.31938,215 shs567,254 shsBEAMBeam Therapeutics$28.64$27.66$15.35▼$36.44$2.95B2.262.24 million shs1.33 million shsDRUGBright Minds Biosciences$83.50$80.83$23.17▼$123.75$812.64M-5.35226,720 shs281,059 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALMSAlumis0.00%-3.72%-11.67%-20.36%+351.23%BEAMBeam Therapeutics0.00%+2.54%+5.64%+1.09%+70.17%DRUGBright Minds Biosciences0.00%+7.78%-6.35%-3.47%+187.83%MORMorphoSys0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALMSAlumis 2.83Moderate Buy$40.3083.02% UpsideBEAMBeam Therapeutics 2.71Moderate Buy$46.8363.52% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$143.8372.26% UpsideMORMorphoSys 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DRUG, MOR, ALMS, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/19/2026ALMSAlumis CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026ALMSAlumis Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $40.005/15/2026ALMSAlumis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$39.005/15/2026ALMSAlumis Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$49.00 ➝ $51.005/15/2026ALMSAlumis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.005/15/2026ALMSAlumis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$25.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.004/20/2026BEAMBeam Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALMSAlumis$24.05M116.73N/AN/A$4.45 per share4.95BEAMBeam Therapeutics$139.74M21.09N/AN/A$11.32 per share2.53DRUGBright Minds BiosciencesN/AN/AN/AN/A$23.11 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALMSAlumis-$243.32M-$1.98N/AN/AN/A-2,825.70%-88.79%-70.72%8/12/2026 (Estimated)BEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ALatest DRUG, MOR, ALMS, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/14/2026Q1 2026ALMSAlumis-$0.7318-$0.74-$0.0082-$0.74$2.10 million$1.74 million5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million3/19/2026Q4 2025ALMSAlumis-$0.90-$0.95-$0.05-$0.94$2.75 million$1.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALMSAlumisN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALMSAlumisN/A7.517.51BEAMBeam Therapeutics0.0916.9916.99DRUGBright Minds BiosciencesN/A81.4757.38MORMorphoSys4.981.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALMSAlumisN/ABEAMBeam Therapeutics99.68%DRUGBright Minds Biosciences40.52%MORMorphoSys18.38%Insider OwnershipCompanyInsider OwnershipALMSAlumis40.70%BEAMBeam Therapeutics3.80%DRUGBright Minds Biosciences42.66%MORMorphoSys0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALMSAlumisN/A127.49 million75.60 millionN/ABEAMBeam Therapeutics510102.88 million98.97 millionOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableDRUG, MOR, ALMS, and BEAM HeadlinesRecent News About These CompaniesPatent case unblocks antibody businessesMay 25 at 9:26 AM | nature.comNNovartis Drug Ianalumab Succeeds in Second IndicationDecember 11, 2025 | thesiliconreview.comTNovartis notches another win for drug acquired in MorphoSys dealDecember 9, 2025 | finance.yahoo.comNovartis drug reduces Sjögren's activity, patient burden in late-stage trials despite notable placebo effectOctober 29, 2025 | fiercebiotech.comFNovartis' Avidity Deal: Growth Accretive, Multiple Gated By ExecutionOctober 27, 2025 | seekingalpha.comMyelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...October 7, 2025 | theglobeandmail.comMorphoSys takeover delivers phase 3 win for NovartisAugust 11, 2025 | pharmaphorum.comPNovartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune diseaseAugust 11, 2025 | biopharmadive.comBMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comVIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphomaJanuary 15, 2025 | healio.comHNovartis closing Morphosys facilities, laying off 330 workersJanuary 8, 2025 | bioworld.comBSwiss pharma giant Novartis to close biotech firm MorphosysDecember 20, 2024 | swissinfo.chSNovartis to shut MorphSys sites amid pelabresib delayDecember 20, 2024 | thepharmaletter.comTNovartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 JobsDecember 19, 2024 | biospace.comBNovartis sheds MorphoSys staff, sites after pelabresib delayDecember 19, 2024 | pharmaphorum.comPNovartis shutters MorphoSys sites, lays off staffDecember 19, 2024 | finance.yahoo.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19, 2024 | reuters.comNovartis raises mid-term sales guidanceNovember 21, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 20262 Stocks to Watch as the Quantum Space Gets More CrowdedBy Nathan Reiff | May 3, 2026Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales TankBy Leo Miller | April 27, 2026Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentBy Nathan Reiff | May 1, 2026DRUG, MOR, ALMS, and BEAM Company DescriptionsAlumis NASDAQ:ALMS$22.02 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$21.74 -0.28 (-1.27%) As of 05/22/2026 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.Beam Therapeutics NASDAQ:BEAM$28.64 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.65 +0.01 (+0.05%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Bright Minds Biosciences NASDAQ:DRUG$83.50 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$83.44 -0.06 (-0.08%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/22/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
